U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07944690) titled 'A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors' on Nov. 12.

Brief Summary: This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of HLX49 in patients with advanced/metastatic solid tumors.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Advanced/Metastatic Solid Tumors

Intervention: DRUG: HLX49

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without...